The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.

Biogen reported the company’s Q3 2020 financial results and stated that R&D would be halted on the experimental multiple sclerosis drug opicinumab.

Shares of Solid Biosciences skyrocketed in trading after the company announced the U.S. Food and Drug Administration lifted the clinical hold on the IGNITE DMD Phase I/II clinical trial.

According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.

Scientists succeeded in reviving microbes retrieved from sediment deep under the seafloor in the heart of the South Pacific that had survived in a dormant state for 101.5 million years in research illustrating the resiliency of life on Earth.

Rebecca Vaught never set out to become an entrepreneur, but that’s exactly what happened when she launched Van Heron Labs during 2020 with a goal of reframing the understanding of the body’s organismal and cellular performance.

Atox Bio had positive results in the company’s Phase III ACCUTE trial for reltecimod for early treatment of severe Necrotizing Soft Tissue Infection (NSTI), a so-called flesh-eating disease.

Researchers at the The Scripps Research Institute found that the strains spreading so quickly in Europe and the U.S. have a mutated S “spike” protein that makes it about 10 times more infectious than the strain that originally was identified in Asia.